Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase.

作者信息

Böger Rainer H, Vallance Patrick, Cooke John P

机构信息

Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany.

出版信息

Atheroscler Suppl. 2003 Dec;4(4):1-3. doi: 10.1016/s1567-5688(03)00027-8.

DOI:10.1016/s1567-5688(03)00027-8

PMID:14664896

Abstract

摘要

相似文献

Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase.

Atheroscler Suppl. 2003 Dec;4(4):1-3. doi: 10.1016/s1567-5688(03)00027-8.

ADMA and oxidative stress.

Atheroscler Suppl. 2003 Dec;4(4):41-51. doi: 10.1016/s1567-5688(03)00033-3.

The DDAH/ADMA/NOS pathway.

Atheroscler Suppl. 2003 Dec;4(4):33-40. doi: 10.1016/s1567-5688(03)00032-1.

Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.

Atheroscler Suppl. 2003 Dec;4(4):61-5. doi: 10.1016/s1567-5688(03)00035-7.

ADMA and hyperhomocysteinemia.

Vasc Med. 2005 Jul;10 Suppl 1:S27-33. doi: 10.1191/1358863x05vm599oa.

Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.

Vasc Med. 2004 May;9(2):93-101. doi: 10.1191/1358863x04vm538oa.

The DDAH-ADMA-NOS pathway.

Ther Drug Monit. 2005 Dec;27(6):744-6. doi: 10.1097/01.ftd.0000179849.42395.11.

Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.

J Nutr. 2004 Oct;134(10 Suppl):2842S-2847S; discussion 2853S. doi: 10.1093/jn/134.10.2842S.

Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).

Vasc Med. 2005 Jul;10 Suppl 1:S49-57. doi: 10.1191/1358863x05vm605oa.

Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.

Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1023-30. doi: 10.1161/01.ATV.0000128897.54893.26. Epub 2004 Apr 22.

引用本文的文献

Pathogenesis of Extraarticular Manifestations in Rheumatoid Arthritis-A Comprehensive Review.

Biomedicines. 2023 Apr 24;11(5):1262. doi: 10.3390/biomedicines11051262.

Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study.

PLoS One. 2018 May 22;13(5):e0197148. doi: 10.1371/journal.pone.0197148. eCollection 2018.

Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis.

Mediators Inflamm. 2018 Jan 18;2018:3897295. doi: 10.1155/2018/3897295. eCollection 2018.

Asymmetric Dimethylarginine Induced Apoptosis and Dysfunction of Endothelial Progenitor Cells: Role of Endoplasmic Reticulum Stress Pathway.

Biomed Res Int. 2017;2017:6395601. doi: 10.1155/2017/6395601. Epub 2017 May 14.

Oxidative Stress and Cardiovascular Aging: Interaction Between NRF-2 and ADMA.

Curr Cardiol Rev. 2017;13(3):183-188. doi: 10.2174/1573403X13666170216150955.

Hyper-activation of pp60 limits nitric oxide signaling by increasing asymmetric dimethylarginine levels during acute lung injury.

Free Radic Biol Med. 2017 Jan;102:217-228. doi: 10.1016/j.freeradbiomed.2016.11.008. Epub 2016 Nov 9.

Oral supplementation with L-homoarginine in young volunteers.

Br J Clin Pharmacol. 2016 Dec;82(6):1477-1485. doi: 10.1111/bcp.13068. Epub 2016 Sep 20.

Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches.

J Korean Med Sci. 2015 Sep;30(9):1213-25. doi: 10.3346/jkms.2015.30.9.1213. Epub 2015 Aug 13.

Chemical biology of protein arginine modifications in epigenetic regulation.

Chem Rev. 2015 Jun 10;115(11):5413-61. doi: 10.1021/acs.chemrev.5b00003. Epub 2015 May 13.

Oxidative damage and antioxidative therapy in systemic sclerosis.

Mediators Inflamm. 2014;2014:389582. doi: 10.1155/2014/389582. Epub 2014 Sep 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase.

Atheroscler Suppl. 2003 Dec;4(4):1-3. doi: 10.1016/s1567-5688(03)00027-8.

ADMA and oxidative stress.

Atheroscler Suppl. 2003 Dec;4(4):41-51. doi: 10.1016/s1567-5688(03)00033-3.

The DDAH/ADMA/NOS pathway.

Atheroscler Suppl. 2003 Dec;4(4):33-40. doi: 10.1016/s1567-5688(03)00032-1.

Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.

Atheroscler Suppl. 2003 Dec;4(4):61-5. doi: 10.1016/s1567-5688(03)00035-7.

ADMA and hyperhomocysteinemia.

Vasc Med. 2005 Jul;10 Suppl 1:S27-33. doi: 10.1191/1358863x05vm599oa.

Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.

Vasc Med. 2004 May;9(2):93-101. doi: 10.1191/1358863x04vm538oa.

The DDAH-ADMA-NOS pathway.

Ther Drug Monit. 2005 Dec;27(6):744-6. doi: 10.1097/01.ftd.0000179849.42395.11.

Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.

J Nutr. 2004 Oct;134(10 Suppl):2842S-2847S; discussion 2853S. doi: 10.1093/jn/134.10.2842S.

Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).

Vasc Med. 2005 Jul;10 Suppl 1:S49-57. doi: 10.1191/1358863x05vm605oa.

Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.

Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1023-30. doi: 10.1161/01.ATV.0000128897.54893.26. Epub 2004 Apr 22.

引用本文的文献

Pathogenesis of Extraarticular Manifestations in Rheumatoid Arthritis-A Comprehensive Review.

Biomedicines. 2023 Apr 24;11(5):1262. doi: 10.3390/biomedicines11051262.

Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study.

PLoS One. 2018 May 22;13(5):e0197148. doi: 10.1371/journal.pone.0197148. eCollection 2018.

Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis.

Mediators Inflamm. 2018 Jan 18;2018:3897295. doi: 10.1155/2018/3897295. eCollection 2018.

Asymmetric Dimethylarginine Induced Apoptosis and Dysfunction of Endothelial Progenitor Cells: Role of Endoplasmic Reticulum Stress Pathway.

Biomed Res Int. 2017;2017:6395601. doi: 10.1155/2017/6395601. Epub 2017 May 14.

Oxidative Stress and Cardiovascular Aging: Interaction Between NRF-2 and ADMA.

Curr Cardiol Rev. 2017;13(3):183-188. doi: 10.2174/1573403X13666170216150955.

Hyper-activation of pp60 limits nitric oxide signaling by increasing asymmetric dimethylarginine levels during acute lung injury.

Free Radic Biol Med. 2017 Jan;102:217-228. doi: 10.1016/j.freeradbiomed.2016.11.008. Epub 2016 Nov 9.

Oral supplementation with L-homoarginine in young volunteers.

Br J Clin Pharmacol. 2016 Dec;82(6):1477-1485. doi: 10.1111/bcp.13068. Epub 2016 Sep 20.

Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches.

J Korean Med Sci. 2015 Sep;30(9):1213-25. doi: 10.3346/jkms.2015.30.9.1213. Epub 2015 Aug 13.

Chemical biology of protein arginine modifications in epigenetic regulation.

Chem Rev. 2015 Jun 10;115(11):5413-61. doi: 10.1021/acs.chemrev.5b00003. Epub 2015 May 13.

Oxidative damage and antioxidative therapy in systemic sclerosis.

Mediators Inflamm. 2014;2014:389582. doi: 10.1155/2014/389582. Epub 2014 Sep 8.